Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

Abstract Background There is a lack of targeted therapeutic options for squamous cell lung cancer (SCC). Accelerated hypertension is an issue with many targeted therapies for lung cancer. This study aimed to analyze the efficacy of anlotinib, based on progression‐free survival (PFS) and overall surv...

Full description

Bibliographic Details
Main Authors: Jianhua Shi, Guimin Chen, Haitao Wang, Xiuxiu Wang, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhian Liu
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Thoracic Cancer
Subjects:
anlotinib
hypertension
lung cancer
squamous cell carcinoma
survival
Online Access:https://doi.org/10.1111/1759-7714.14076

Internet

https://doi.org/10.1111/1759-7714.14076

Similar Items